Get to know our clinical trials
Phase I clinical trial of RO7589831 in participants with advanced solid tumors.
THE PRIMARY OBJECTIVE OF THIS TRIAL IS TO DETERMINE WHETHER RO7589831 ADMINISTERED AT DIFFERENT DOSES HAS EFFECTS, WHETHER POSITIVE OR NEGATIVE, AS WELL AS WHAT HAPPENS TO RO7589831 ONCE IT ENTERS THE BODY AND HOW IT ACTS IN THE BODY AND ON YOUR DISEASE.
Cancer Center
Status
In recruitment
headquarters
Pamplona/Madrid
Early phase
Technical Summary
- OPEN-LABEL PHASE I STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS, AND ANTITUMOR ACTIVITY OF RO7589831 IN PARTICIPANTS WITH ADVANCED SOLID TUMORS WITH HIGH MICROSATELLITE INSTABILITY (MSI-H) AND/OR DEFICIENT MISMATCH REPAIR (DMMR).
- Code EudraCT: 2023-503170-20-00
- Protocol number: VVD-133214-01
- Promoter: Vivideon Therapeutics
- Molecule/Drug: RO7589831
- Link to Clinical Trials
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.